Coumarin derivatives constitute a versatile small-molecule chemotype with broad anticancer potential. This narrative review synthesizes recent in vitro and in vivo evidence on coumarin-based scaffolds, emphasizing breast cancer and covering lung, prostate, and colorectal models. We summarize major mechanisms of action—including induction of apoptosis (caspase activation and BAX/BCL-2 balance), modulation of PI3K/Akt/mTOR signaling, inhibition of angiogenesis (VEGFR-2), interference with estrogen biosynthesis (aromatase/ER axis), chaperone targeting (Hsp90), and attenuation of multidrug resistance (efflux pumps/autophagy)—and highlight representative chemotypes (e.g., benzimidazole, triazole, furocoumarins, topoisomerase- and CDK-oriented hybrids). Where available, we contrast potency and selectivity across models (e.g., MCF-7 vs. MDA-MB-231; A549; PC-3; colon lines) and discuss structure–activity trends linking substituent patterns (heteroaryl linkers, judicious halogenation, polar handles) to pathway engagement. We also delineate translational gaps limiting clinical progress—selectivity versus non-malignant cells, incomplete pharmacokinetic and safety characterization, and limited validation beyond xenografts. Finally, we outline priorities for preclinical optimization: biology-aligned target selection with biomarkers, resistance-aware combinations (e.g., PI3K/mTOR ± autophagy modulation; MDR mitigation), and early integration of ADME/tox and PK/PD to confirm on-target exposure. Collectively, the evidence supports coumarins as adaptable, multi-target anticancer leads, particularly promising in hormone-dependent breast cancer while remaining relevant to other tumor types.

Pyrazole derivatives have emerged as an important class of heterocyclic compounds in anticancer research due to their structural versatility and broad spectrum of biological activities. This review provides a concise overview of recent advances in the development of pyrazole-based anticancer agents, with emphasis on synthetic strategies, structure–activity relationships, and molecular mechanisms of action. Common synthetic approaches, particularly condensation and cyclization reactions, have enabled the preparation of structurally diverse pyrazole derivatives for biological evaluation. Available evidence indicates that the type and position of substituents within the pyrazole scaffold markedly influence anticancer potency, selectivity, and target affinity. Reported compounds act through multiple mechanisms, including inhibition of cancer-related targets such as tubulin, epidermal growth factor receptor (EGFR), cyclin-dependent kinases (CDKs), Bruton tyrosine kinase (BTK), and deoxyribonucleic acid (DNA)-associated pathways, as well as induction of apoptosis and disruption of cell-cycle progression. Several pyrazole derivatives have shown promising activity in in vitro and in vivo models. Overall, the findings summarized in this review identify the pyrazole scaffold as a valuable platform for the design and optimization of novel anticancer agents and support its continued exploration in medicinal chemistry.

Epilepsy is a chronic neurological disorder affecting approximately 50 million individuals worldwide. It poses a significant challenge like osteoporosis, Stevens-Johnson syndrome, agranulocytosis, aplastic anemia, hepatic failure, pancytopenia, multiorgan hypersensitivity, and psychosis due to limited efficacy of currently available antiepileptic drugs (AEDs). The heterocyclic rings thiophene and 1,5-benzothiazepine have been studied extensively for their antiepileptic activity. This study synthesized a series of new thiophene-incorporated 1,5-benzothiazepine derivatives. The synthetic technique involved the condensation of ketomethylene with malononitrile to form a Knoevenagel–Cope condensation product, which cyclizes with sulfur and diethyl amine to give a 2-aminothiophene derivative. This forms thienyl chalcones upon treatment with different substituted benzaldehyde in ethanol and sodium hydroxide as a base at room temperature. Upon refluxing with o-amino thiophenol, these chalcones form corresponding thiophene-incorporated benzothiazepine derivatives. The structure of these compounds was confirmed by IR, 1H NMR, and Mass spectroscopy. Compound TBA5 was subjected to in vivo antiepileptic activity by Maximal electroshock induced seizure and Pentylenetetrazole induced seizure model. Compound TBA5, in three different dosage levels (low, medium, high), effectively decreased convulsions compared to the control. Hence, the findings highlight the potential of the newly designed compound TBA5 as a viable option for further exploration as an antiepileptic medication.

Colorectal carcinoma (CRC) exerts a growing global disease burden, with microsatellite-stable/proficient mismatch repair (MSS/pMMR) tumors exhibiting intrinsic refractoriness to immune-checkpoint blockade (ICB) owing to low tumor mutational burden, limited neoantigenicity, and an immunosuppressive tumor microenvironment (TME) dominated by regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This review evaluates induced pluripotent stem cell (iPSC)–derived polyvalent vaccines as ontogenetically recapitulative immunogens capable of reinstating broad antitumor immunity. Reprogramming induces re-expression of oncofetal tumor-associated antigens, including cancer-testis antigens (NY-ESO-1, MAGE-A3), aberrant glycoforms of CEA and MUC1, and clinically actionable neoepitopes such as KRAS^G12D/V, thereby promoting epitope spreading and immunogenic cell death. Irradiated autologous or syngeneic iPSCs, delivered with Toll-like receptor 9 agonists, facilitate robust MHC I/II cross-presentation, driving CD8⁺ cytotoxic T-cell activation, Th1 polarization, perforin/granzyme-mediated cytolysis, and favorable effector-to-suppressor ratios. Preclinical models of melanoma, pancreatic ductal adenocarcinoma, and MSS CRC demonstrate prophylactic and therapeutic efficacy, with neoantigen-enhanced iPSCs synergizing with radiotherapy-induced DAMPs to achieve durable regressions and memory T-cell formation. Translational priorities include CRISPR-engineered hypoimmunogenic iPSC platforms, GMP-compatible non-integrating reprogramming, and combinatorial integration with STING agonists, ICB, CAR-NK cells, and LNP-mRNA constructs to enable biomarker-guided clinical deployment in minimal-residual-disease CRC.

Quality assurance in the pharmaceutical industry aims to ensure that the product that reaches the patient is safe, effective, and of better quality. Product quality is checked by various activities of quality systems such as managerial and technical, including evaluation of pharmaceutical products documentation, performing or reviewing quality-control laboratory tests, and monitoring product performance. Managerial activities include selecting reliable suppliers, preparing contract terms, monitoring supplier performance, and performing inspection trials during the distribution network. Compliance Services assures that the labs are operating within global regulatory requirements. By assuring the provider agrees on the protocols under a single Universal Operational Qualification framework, it will have a comprehensive, automated approach to investigation, documentation, and agreement, streamlining processes across all leading pharmaceutical industry models. In pharmaceutical industries, tablet dosage forms should follow the Q10 guidelines of ICH. The models and statistical approaches should qualify as per the guidelines. Observation should be done throughout the life cycle of the tablet dosage form.